Maura L. Gillison

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-8145-5749

发表论文 625 篇 · 总被引 60735 次 · h-index 99

代表论文

Abstract LB485: Integrative analyses of cervical cancer and patient-derived organoids uncover signaling and metabolic circuits associated with therapy-resistant (2026 · Cancer Research)
Abstract 49: The PER3-RORB axis defines a tumor-suppressive circadian state associated with improved survival in head and neck squamous cell carcinoma. (2026 · Cancer Research)
Supplementary Table 13 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial (2026)
Supplementary Figure 5 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial (2026)
Supplementary Table 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial (2026)
Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial (2026)